An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu klinické zkoušky, fáze II, časopisecké články, randomizované kontrolované studie, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
35536547
DOI
10.1158/1078-0432.ccr-21-4413
PII: 696491
Knihovny.cz E-zdroje
- MeSH
- dendritické buňky MeSH
- epiteliální ovariální karcinom * genetika terapie MeSH
- lidé MeSH
- mutace MeSH
- nádorové biomarkery MeSH
- nádory vaječníků * genetika terapie MeSH
- protinádorové vakcíny * terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Názvy látek
- nádorové biomarkery MeSH
- protinádorové vakcíny * MeSH
PURPOSE: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical management of various solid tumors has raised considerable expectations for patients with epithelial ovarian carcinoma (EOC). However, EOC is poorly responsive to ICIs due to immunologic features including limited tumor mutational burden (TMB) and poor lymphocytic infiltration. An autologous dendritic cell (DC)-based vaccine (DCVAC) has recently been shown to be safe and to significantly improve progression-free survival (PFS) in a randomized phase II clinical trial enrolling patients with EOC (SOV01, NCT02107937). PATIENTS AND METHODS: We harnessed sequencing, flow cytometry, multispectral immunofluorescence microscopy, and IHC to analyze (pretreatment) tumor and (pretreatment and posttreatment) peripheral blood samples from 82 patients enrolled in SOV01, with the aim of identifying immunologic biomarkers that would improve the clinical management of patients with EOC treated with DCVAC. RESULTS: Although higher-than-median TMB and abundant CD8+ T-cell infiltration were associated with superior clinical benefits in patients with EOC receiving standard-of-care chemotherapy, the same did not hold true in women receiving DCVAC. Conversely, superior clinical responses to DCVAC were observed in patients with lower-than-median TMB and scarce CD8+ T-cell infiltration. Such responses were accompanied by signs of improved effector functions and tumor-specific cytotoxicity in the peripheral blood. CONCLUSIONS: Our findings suggest that while patients with highly infiltrated, "hot" EOCs benefit from chemotherapy, women with "cold" EOCs may instead require DC-based vaccination to jumpstart clinically relevant anticancer immune responses.
Caryl and Israel Englander Institute for Precision Medicine Weill Cornell Medicine New York New York
Centre De Recherche Des Cordeliers INSERM Sorbonne Université Université De Paris Paris France
Department of Gynaecology and Obstetrics Leuven Cancer Institute UZ Leuven Leuven Belgium
Department of Radiation Oncology Weill Cornell Medicine New York New York
Equipe Labellisée Ligue Contre Le Cancer Paris France
INSERM UMRS1138 Laboratory of Integrative Cancer Immunology Cordeliers Research Center Paris France
Sandra and Edward Meyer Cancer Center Weill Cornell Medicine New York New York
Citace poskytuje Crossref.org
Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
ClinicalTrials.gov
NCT02107937
